Dr Agarwal's Eye Hospital's merger scheme has received unanimous approval from its secured creditors. This crucial step paves the way for the amalgamation with Dr. Agarwal's Health Care Limited, moving closer to final NCLT sanction.
Dr Agarwal's Eye Hospital Merger Clears Key Hurdle
Dr Agarwal's Eye Hospital Ltd merger scheme approved by 100% of secured creditors; Total valid votes cast were ₹85.77 crore. Reader Takeaway: Unanimous creditor approval removes a major merger roadblock, signaling regulatory progress. ## What Just Happened Dr Agarwal's Eye Hospital Ltd announced that its Scheme of Amalgamation with Dr. Agarwal's Health Care Limited has been approved by 100% of its secured creditors. The approval came during a meeting convened by the National Company Law Tribunal (NCLT) on July 02, 2026. ## Why This Matters This unanimous approval from secured creditors, representing ₹85.77 crore in value, is a critical legal and procedural milestone. It signifies that a major stakeholder group has agreed to the terms of the merger, removing a significant obstacle to the corporate restructuring. ## The Backstory The Scheme of Amalgamation is being pursued under Sections 230 to 232 of the Companies Act, 2013. Such schemes require approvals from various classes of creditors and shareholders, along with regulatory bodies like the NCLT. Obtaining 100% consent from secured creditors demonstrates strong alignment among this group. ## What Changes Now With the secured creditors' approval secured, the amalgamation process moves to the next stage, which involves seeking final sanction from the NCLT. This is a procedural step, and the actual financial and operational integration will follow once the NCLT gives its final order. ## Risks to Watch While this is a positive development, the final approval from the NCLT is still pending. Any unforeseen issues or objections raised during the NCLT's review process could potentially delay or alter the scheme. ## Peer Comparison Mergers and acquisitions in the healthcare sector often involve complex approval processes. Achieving unanimous consent from secured creditors is a strong outcome, setting a positive precedent for the remaining stages of Dr Agarwal's restructuring. ## Context Metrics (Time-bound) - **Meeting Date:** July 02, 2026 - **Creditor Approval:** 100% of secured creditors - **Total Valid Votes Cast:** ₹85.77 crore (₹8,577.34 lakh) ## What to Track Next Investors should closely monitor future filings for updates on the NCLT's decision regarding the final sanction of the Scheme of Amalgamation. The successful completion of the merger is key to the company's future growth strategy.
